Reference is made to the announcement by Statoil ASA (the "Company", OSE: STL, NYSE:STO) on 22 September 2016 regarding the participation by the primary insiders in the dividend issues under the scrip dividend programme for first quarter 2016.
Further reference is made to the stock market announcement on 14 December 2016 regarding allocation to primary insiders of shares under the share saving plan.
Details on allocation of the Dividend Shares for the second quarter 2016 are set forth in the attached overview.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/e351680b-5db3-4c6c-952b-8bf0820451ba
Peter Hutton, SVP Investor Relations, mbl: +44 7881 918 792 Morten Sven Johannessen, VP Investor Relations USA, mbl +1 203 570 2524


Luxury Car Sales in the Middle East Take a Hit Amid Iran War
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage
Apple Turns 50: From Garage Startup to AI Crossroads
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 



